CTRI/2022/02/040186
Not yet recruiting
Phase 2
Role of Rituximab in maintaining long term remission of idiopathic steroid dependent and steroid resistant nephrotic syndrpme - RITUXIMAINS
Dr Arpita Raychaudhury0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Arpita Raychaudhury
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with idiopathic nephrotic syndrome with steroid
- •dependence or frequent relapses who has failed at least one steroid
- •sparing agent.
- •2\) Secondary steroid resistant nephrotic syndrome with return of steroid sensitivity during treatment of relapse,failing at leat one immunosuppressant other than steroid.
- •3\) In remission state or 24 hr urine protein \< 1gm
- •4\) Those who have given informed written consent
Exclusion Criteria
- •1\) Primary steroid resistant nephrotic syndrome
- •2\) Secondary cause of nephrotic syndrome
- •3\) Genetic cause of nephrotic syndrome 4\) Hepatitis B and C serology positive
- •5\) Acute or chronic active infection
- •6\) Chronic lung disease or uncontrolled asthma
- •7\) Leucopenia or thrombocytopenia
- •8\) ALT/AST \>2\.5 times upper limit of normal
- •9\) Expected rituximab first infusion date less than 4 weeks from a live
- •vaccination
- •10\) Regular follow\-up not feasible
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaCD20+ Aggressive Lymphoma, Mantle Cell LymphomaNCT01933711University Hospital Heidelberg328
Active, not recruiting
Phase 1
Maintenance treatment With rituximab in ITPEUCTR2015-005276-14-DKSykehuset Østfold HF130
Completed
Phase 3
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)Chronic Lymphocytic LeukemiaNCT01118234Arbeitsgemeinschaft medikamentoese Tumortherapie256
Active, not recruiting
Phase 3
The PROLONG Trial - Rituximab Maintenance Therapy in ITPPurpura, Thrombocytopenic, IdiopathicNCT03010202Ostfold Hospital Trust136
Completed
Phase 2
Rituximab in treatment of Rheumatoid arthritis in Indian patientsHealth Condition 1: null- Rheumatoid arthritisHealth Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvementCTRI/2017/08/009321CENTER FOR RHEUMATIC DISEASES60